The analysis was conducted by researchers from the University of Michigan.

90 % of women who got undergone a double mastectomy said that they had been worried sick about the possibility of recurrence. Yet, based on the researchers’ assessment of the actual risk of recurrence, a full 70 % of ladies who underwent contralateral prophylactic mastectomy had done so without good trigger. That’s because in almost all cases, a analysis of cancer in a single breast isn’t correlated with an elevated risk of malignancy in the other breast. ‘Women look like using worry over malignancy recurrence to select contralateral prophylactic mastectomy,’ researcher Sarah Hawley stated. ‘This does not make sense, because having a non-affected breast removed won’t reduce the threat of recurrence in the affected breasts.’ ‘Not appropriate’The only women in whom cancer in one breast is connected with a risk of tumor in the other breast are those with the history of breast or ovarian cancer in two or more immediate family members, or with a particular mutation in the BRCA1 or BRCA2 genes.During the follow-up period, there have been 90 heart-related events, 141 cases of tumor, and 71 deaths from all causes among the participants. Although the team didn’t come to a firm cause because of their conclusion, they claim that ectopic fat, defined as excess fat present where it shouldn’t be, leads to unwanted fat stores around organs recognized to promote systemic metabolic dysfunction and elevated disease risk. Proof continues to mount in support of maintaining an optimal body weight, and how losing small amounts of body fat help to reduce the risk of succumbing to the devastating effects seen with heart disease and cancer.

Advaxis reports continued positive individual survival design in ADXS-HPV Phase 2 cervical cancer trial Advaxis, Inc., , a head in developing another era of immunotherapies for tumor and infectious diseases, presented updated preliminary data from a continuing randomized Stage 2 trial of ADXS-HPV being conducted in India in females with recurrent/refractory cervical malignancy who have failed previous cytotoxic therapy.